Amendment to Schedule 13D Filing for Rallybio Corp

This filing is an amendment to a Schedule 13D, originally filed on August 12, 2021, and previously amended on January 18, 2022. It concerns the Common Stock of Rallybio Corp. The amendment restates various items, including details about the reporting persons (TPG GP A, LLC, James G. Coulter, and Jon Winkelried), their principal occupations, and business addresses. A key update is the information regarding a Merger Agreement entered into on March 1, 2026, between Rallybio Corp, Candid Therapeutics, Inc., and Farmington Merger Sub, Inc. In connection with this merger, one of the reporting entities, Rise Fund Rascal, entered into a Support Agreement, committing to vote its shares in favor of the merger and not to solicit alternative proposals. The filing also details that TPG GP A, LLC, James G. Coulter, and Jon Winkelried may be deemed to beneficially own 378,551 shares of Rallybio Corp's Common Stock, representing approximately 7.2% of the outstanding shares as of February 26, 2026. No other plans or proposals related to the matters listed in Schedule 13D Items 4(a)-(j) are currently disclosed, though the reporting persons reserve the right to change their position.